Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03902951 · ClinicalTrials.gov registry record · Phase 2

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

A Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Recurrent Prostate Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.

Active
Registry status
Phase 2
Development phase
28
Enrollment target
1
Study location

NCT03902951 is a Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Recurrent Prostate Carcinoma that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 28 participants, below the 177-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03902951, a Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Recurrent Prostate Carcinoma, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies how well antiandrogen therapy (leuprolide, apalutamide, and abiraterone acetate) and stereotactic body radiation therapy (SBRT) works in treating patients with prostate cancer that has come back and has spread to other parts of the body. Drugs used in chemotherapy, such as leuprolide, apalutamide, and abiraterone acetate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving antiandrogen therapy and SBRT may work better in treating patients with prostate cancer.

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • DRUG Apalutamide
  • DRUG Abiraterone Acetate
  • DRUG Leuprolide Acetate

Study Locations (1)

California

  • UCLA / Jonsson Comprehensive Cancer Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2021-03-17
Est. Completion 2028-01-01
Phase Phase 2

Sponsor

Jonsson Comprehensive Cancer Center

321 total trials

What the Registry Record Tells You About NCT03902951

The ClinicalTrials.gov registry entry for NCT03902951 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 177-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (84% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Stage IVB Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.

NCT03902951 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03902951 about?

NCT03902951 is a clinical study titled "Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer". This phase II trial studies how well antiandrogen therapy (leuprolide, apalutamide, and abiraterone acetate) and stereotactic body radiation therapy (SBRT) works in treating patients with prostate cancer that has come back and has spread to other parts of the body. Drugs used in chemotherapy, such a...

What is the current status of trial NCT03902951?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2021-03-17. Estimated completion is 2028-01-01.

What conditions does trial NCT03902951 study?

This clinical trial studies the following conditions: Stage IVB Prostate Cancer AJCC v8, Recurrent Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation.

What interventions are being tested in trial NCT03902951?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Apalutamide (DRUG), Abiraterone Acetate (DRUG), Leuprolide Acetate (DRUG).

Who is sponsoring clinical trial NCT03902951?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03902951 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stage IVB Prostate Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.